Michael Owen
Director/Board Member chez SAREUM HOLDINGS PLC
Fortune : 727 650 $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Michael Elliot Hunt | M | 62 |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | 23 ans |
John Hawkins | M | 58 | 10 ans | |
Tony Gardiner | M | 53 |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | 8 ans |
John Reader | M | 56 | 21 ans | |
Amit Chunilal Nathwani | M | 64 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 5 ans |
Olav Hellebø | M | 59 |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | 10 ans |
Frank S. Walsh | M | - |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | 13 ans |
Alf Gunnar Martin Nicklasson | M | 69 | 9 ans | |
Simon Cartmell | M | 64 |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | 10 ans |
Clive Birch | M | 70 | 6 ans | |
Timothy Mitchell | M | 63 | 21 ans | |
Corey Goodman | M | 72 |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | 13 ans |
Eliot Forster | M | 58 |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | 6 ans |
Bernadette Connaughton | F | 65 | 5 ans | |
Bengt Westermark | M | 79 |
European Molecular Biology Organization
| - |
J. Lynn Rutkowski | M | - |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | - |
Jeffrey Berkowitz | M | 58 | 5 ans | |
Ivan M. Møller | M | 52 | 6 ans | |
Martin Walton | M | 61 | 2 ans | |
Nilesh Modi | M | 55 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Trevor Nicholls | M | 67 |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | - |
Barbara Staehelin | F | 61 | 3 ans | |
Alastair Smith | M | - |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | - |
Paul Fry | M | 58 | 4 ans | |
Kirsten Drejer | M | 68 | 6 ans | |
Peter Goodfellow | M | 72 |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | 9 ans |
Leonard Kruimer | M | 66 | 5 ans | |
Sally Jackson | F | - | 23 ans | |
Patrick Baeuerle | M | 66 |
European Molecular Biology Organization
| - |
Antonio Lanzavecchia | M | 73 |
European Molecular Biology Organization
| - |
Samit Govindji Hathi | M | 57 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Karen Vousden | M | 66 |
European Molecular Biology Organization
| - |
Bharat Kumar Hirji Thakrar | M | 67 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Rudy Dekeyser | M | 63 |
The European Molecular Biology Laboratory
| - |
Seung Suh Hong | M | 66 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 3 ans |
Erkki Ruoslahti | M | 84 |
European Molecular Biology Organization
| - |
Brian Silver | M | 55 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Christina Sonnenborg Bredal | F | 39 | 4 ans | |
Anneline Nansen | F | 55 | 3 ans | |
David Glover | M | - |
European Molecular Biology Organization
| - |
Edith Heard | F | - |
The European Molecular Biology Laboratory
| - |
Henriette Wennicke | F | - | 2 ans | |
Fulvio Mavilio | M | - |
European Molecular Biology Organization
| - |
Steve Moore | M | - |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | 12 ans |
David M. Kendall | M | 62 | 2 ans | |
Peter Andersen | M | 67 |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | - |
Peter Ratcliffe | M | 69 |
European Molecular Biology Organization
| - |
Joe D. Lewis | M | 57 |
The European Molecular Biology Laboratory
| - |
Laurence Harris Pearl | M | - |
European Molecular Biology Organization
| - |
Spyridon Artavanis-Tsakonas | M | 77 |
European Molecular Biology Organization
| - |
Ashok Venkitaraman | M | - |
European Molecular Biology Organization
| - |
Luke O'Neill | M | 60 |
European Molecular Biology Organization
| 19 ans |
Robert Kamen | M | 79 |
European Molecular Biology Organization
| 48 ans |
Alan R. Williamson | M | 87 |
The European Molecular Biology Laboratory
| - |
Hermona Soreq | M | - |
European Molecular Biology Organization
| - |
Victoria Whyte | F | - | 15 ans | |
Stephen Philip Jackson | M | - |
European Molecular Biology Organization
| 27 ans |
Raymond Kaempfer | M | - |
European Molecular Biology Organization
| - |
Daniel L. Farkas | M | 70 |
European Molecular Biology Organization
| - |
Paul Schulze Lefert | M | - |
European Molecular Biology Organization
| - |
Dirk Heinz | M | - |
European Molecular Biology Organization
| 15 ans |
Yigong Shi | M | 57 |
European Molecular Biology Organization
| - |
Anita Kidgell | F | - | 16 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Catherine Isted | F | - | 2 ans | |
John Berriman | M | 76 | 9 ans | |
Moncef Slaoui | M | 64 | 11 ans | |
Timothy Sykes | M | 55 | 9 ans | |
Timothy Corn | M | 73 | 10 ans | |
John Hyttel | M | 78 | 15 ans | |
Stephanie Burns | M | 69 | 9 ans | |
Belita S. Ong | F | - |
University of Cambridge
| 4 ans |
Daniel Podolsky | M | 70 | 10 ans | |
Roy Anderson | M | 76 | 11 ans | |
David Solomon | M | 63 | 7 ans | |
Alain Munoz | M | 75 | 17 ans | |
Christopher Viehbacher | M | 64 | 20 ans | |
Hanne Leth Hillman | F | 59 | 5 ans | |
Gregory Winter | M | 73 |
University of Cambridge
| 7 ans |
Rosemary Crane | F | 64 | 4 ans | |
Patrick J. T. Vallance | M | 64 | - | |
Mads Vindahl Kronborg | M | - | - | |
Chong Kiat Lim | M | 68 |
University of Cambridge
| 7 ans |
Gareth Beynon | M | - |
University of Cambridge
| 6 ans |
Eva Steiness | M | 83 | 19 ans | |
Richard Sykes | M | 79 | 7 ans | |
Jean-Pierre Garnier | M | 75 | 8 ans | |
H. Culp | M | 60 | 9 ans | |
Deryck Charles Maughan | M | 76 | 12 ans | |
Ian Maurice Gray Prosser | M | 81 | 9 ans | |
Robert Wilson | M | 81 | 11 ans | |
Christopher Gent | M | 75 | 11 ans | |
John David Coombe | M | 79 | 5 ans | |
Peter Traber | M | 69 | 3 ans | |
Michèle Barzach | M | - | 7 ans | |
James Murdoch | M | 51 | 3 ans | |
Crispin Davis | M | 75 | 10 ans | |
Tom de Swaan | M | 78 | 9 ans | |
Bahman Yamini | M | - |
University of Cambridge
| 5 ans |
Alex Howarth | M | 55 | 10 ans | |
Rasmus Just | M | 48 | 14 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Royaume-Uni | 53 | 53,00% |
Allemagne | 24 | 24,00% |
Danemark | 18 | 18,00% |
Etats-Unis | 5 | 5,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Michael Owen
- Réseau Personnel